Clinical trial
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder…
NCT00224016 · Watson Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00224016 |
|---|---|
| Title | Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition |
| Official title | A Multi-Center, Open-Label (OL), Active-Controlled, Dose-Titration Study Evaluating the Safety, Efficacy and PK of Oxybutynin Transdermal Systems in the Treatment of Detrusor Overactivity in Pediatric Patients |
| Lead sponsor | Watson Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Detrusor Hyperreflexia |
| Intervention type | Drug |
| Interventions | Oxybutynin |
| Enrollment | 57 |
| Start date | Dec 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Sep 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Feb 9, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: